Effects of Short-term Growth Hormone in HIV-infected Patients

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00795210

First Posted: November 21, 2008

Last Update Posted: January 8, 2014

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborator:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Information provided by (Responsible Party):

Steven K. Grinspoon, MD, Massachusetts General Hospital

Results First Submitted: October 9, 2013

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition:	HIV Lipodystrophy
Interventions:	Drug: Growth hormone Drug: Growth Hormone Releasing Hormone

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment occurred between January, 2009 and November, 2012, in the Boston area.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Once patients were found to be eligible (after screen visit) and agreed to participate, there were no additional events prior to baseline.

Reporting Groups

	Description
GH 6mcg/kg/d	Recombinant human growth hormone 6mcg/kg SC once daily
GH 2mg Daily	Recombinant human growth hormone 2mg SC once daily
Growth Hormone Releasing Hormone	Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks

Participant Flow: Overall Study

	GH 6mcg/kg/d	GH 2mg Daily	Growth Hormone Releasing Hormone
STARTED	8	12	5
COMPLETED	8	11	3
NOT COMPLETED	0	1	2

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
GH 6mcg/kg/d	Recombinant human growth hormone 6mcg/kg SC once daily
GH 2mg Daily	Recombinant human growth hormone 2mg SC once daily
Growth Hormone Releasing Hormone	Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks
Total	Total of all reporting groups

Baseline Measures

	GH 6mcg/kg/d	GH 2mg Daily	Growth Hormone Releasing Hormone	Total
Overall Participants Analyzed [Units: Participants]	8	12	5	25

Age [Units: Participants]
<=18 years	0	0	0	0
Between 18 and 65 years	8	12	5	25
>=65 years	0	0	0	0

Age [Units: Years] Mean (Standard Deviation)	49 (7)	49 (6)	47 (4)	48 (6)

Gender [Units: Participants]
Female	0	2	0	2
Male	8	10	5	23

Region of Enrollment [Units: Participants]
United States	8	12	5	25

Outcome Measures

Show All Outcome Measures

1. Primary:

Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug [ Time Frame: after 2 weeks treatment ]

Show Outcome Measure 1

2. Secondary:

Insulin Sensitivity [ Time Frame: after two weeks treatment ]

Show Outcome Measure 2

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The study was completed early due to the lack of availability of study drug for one of the arms.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Steven Grinspoon, MD
Organization: Massachusetts General Hospital
phone: 617-724-9109
e-mail: sgrinspoon@partners.org

Responsible Party:	Steven K. Grinspoon, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00795210 History of Changes
Other Study ID Numbers:	DK63639A R01DK063639 ( U.S. NIH Grant/Contract )
First Submitted:	November 20, 2008
First Posted:	November 21, 2008
Results First Submitted:	October 9, 2013
Results First Posted:	January 8, 2014
Last Update Posted:	January 8, 2014

To Top